[go: up one dir, main page]

AR052741A1 - Acidos nucleicos de union a ghrelin - Google Patents

Acidos nucleicos de union a ghrelin

Info

Publication number
AR052741A1
AR052741A1 ARP060101371A ARP060101371A AR052741A1 AR 052741 A1 AR052741 A1 AR 052741A1 AR P060101371 A ARP060101371 A AR P060101371A AR P060101371 A ARP060101371 A AR P060101371A AR 052741 A1 AR052741 A1 AR 052741A1
Authority
AR
Argentina
Prior art keywords
section
ghrelin
union
nucleic acids
box
Prior art date
Application number
ARP060101371A
Other languages
English (en)
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of AR052741A1 publication Critical patent/AR052741A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)

Abstract

Se refiere a un ácido nucleico, preferiblemente de union a ghrelin, en el que el ácido nucleico comprende una primera casilla de tramo A, y una segunda casilla de tramo B, en la que la primera casilla A del tramo comprende aproximadamente seis a ocho nucleotidos consecutivos, en el que un tramo 3' terminal de nucleotidos de la primera casilla A del tramo se híbrida con la segunda casilla B del tramo, donde tras la hibridacion se forma una primera estructura de doble cadena, donde tal primera estructura de doble cadena comprende una protuberancia.
ARP060101371A 2005-04-08 2006-04-06 Acidos nucleicos de union a ghrelin AR052741A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05007795 2005-04-08

Publications (1)

Publication Number Publication Date
AR052741A1 true AR052741A1 (es) 2007-03-28

Family

ID=37087373

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101371A AR052741A1 (es) 2005-04-08 2006-04-06 Acidos nucleicos de union a ghrelin

Country Status (24)

Country Link
US (2) US8101734B2 (es)
EP (1) EP1866412A2 (es)
JP (2) JP5308813B2 (es)
KR (1) KR20080009072A (es)
CN (1) CN101189337B (es)
AP (1) AP2007004189A0 (es)
AR (1) AR052741A1 (es)
AU (1) AU2006233647A1 (es)
BR (1) BRPI0608180A2 (es)
CA (1) CA2605377A1 (es)
CR (1) CR9423A (es)
DO (1) DOP2006000085A (es)
EA (1) EA200701901A1 (es)
GB (1) GB2439673A (es)
GT (1) GT200600137A (es)
IL (1) IL186085A0 (es)
MA (1) MA29384B1 (es)
MX (1) MX2007012419A (es)
NL (2) NL1031538C2 (es)
PE (1) PE20061358A1 (es)
TN (1) TNSN07375A1 (es)
TW (1) TW200718781A (es)
UY (1) UY29460A1 (es)
WO (1) WO2006108599A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013274A2 (en) * 2002-08-01 2004-02-12 Noxxon Pharma Ag Ghrelin binding nucleic acids
JP4823067B2 (ja) * 2003-11-10 2011-11-24 ノクソン・フアルマ・アクチエンゲゼルシヤフト 生物活性グレリンに特異的に結合する核酸
UY29460A1 (es) * 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
PT2274331E (pt) 2008-05-02 2014-02-27 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP3597666A3 (en) 2011-07-01 2020-04-22 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
PL2938740T3 (pl) 2012-12-27 2022-07-11 Ngm Biopharmaceuticals, Inc. Chimeryczne peptydy fgf19 do zastosowania w leczeniu zaburzeń gospodarki kwasami żółciowymi
US9943568B2 (en) 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP2017536098A (ja) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
PE20180670A1 (es) 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
EP3341012B1 (en) 2015-08-25 2025-07-30 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
JP2019513373A (ja) 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
KR102565256B1 (ko) 2017-02-12 2023-08-08 바이오엔테크 유에스 인크. Hla 기반 방법 및 조성물, 및 이들의 용도
JP7544598B2 (ja) 2017-11-10 2024-09-03 アーモ・バイオサイエンシーズ・インコーポレイテッド 免疫チェックポイント経路阻害剤と併用したインターロイキン－１０の組成物および使用方法
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020083898A1 (en) 2018-10-24 2020-04-30 F. Hoffmann-La Roche Ag Process for the purification of oligonucleotides
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020132586A1 (en) 2018-12-21 2020-06-25 Neon Therapeutics, Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
JP7726067B2 (ja) * 2019-06-11 2025-08-20 味の素株式会社 ペプチド及びその用途
EP3982980A4 (en) 2019-06-12 2023-11-29 BioNTech US Inc. NEOANTIGEN COMPOSITIONS AND USES THEREOF
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US20230277618A1 (en) 2020-08-07 2023-09-07 The Broad Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
EP4259206A4 (en) 2020-12-14 2025-07-09 Biontech Us Inc TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
CA2084987C (en) * 1990-06-11 2007-02-13 Larry Gold Nucleic acid ligands
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
EP0825997A1 (en) 1995-05-03 1998-03-04 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
DE19808591C2 (de) 1998-02-28 2000-02-03 Univ Leipzig Standardisierter durchflußzytometrischer Vollblutassay
US20030211967A1 (en) * 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
AU2001259056A1 (en) 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
JP2004514651A (ja) 2000-05-30 2004-05-20 メルク　エンド　カムパニー　インコーポレーテッド グレリン類似体
DK1438321T5 (da) * 2001-10-26 2011-02-21 Noxxon Pharma Ag Modificeret L-nukleinsyre
WO2004013274A2 (en) 2002-08-01 2004-02-12 Noxxon Pharma Ag Ghrelin binding nucleic acids
JP4823067B2 (ja) 2003-11-10 2011-11-24 ノクソン・フアルマ・アクチエンゲゼルシヤフト 生物活性グレリンに特異的に結合する核酸
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Also Published As

Publication number Publication date
US20060258607A1 (en) 2006-11-16
JP2013176372A (ja) 2013-09-09
AP2007004189A0 (en) 2007-10-31
US8101734B2 (en) 2012-01-24
AU2006233647A2 (en) 2008-04-17
NL1033520C2 (nl) 2010-01-21
NL1031538C2 (nl) 2007-03-20
UY29460A1 (es) 2006-11-30
DOP2006000085A (es) 2006-11-15
GT200600137A (es) 2006-11-22
CA2605377A1 (en) 2006-10-19
TNSN07375A1 (fr) 2009-03-17
CN101189337A (zh) 2008-05-28
CN101189337B (zh) 2013-11-06
US20120115937A1 (en) 2012-05-10
JP5308813B2 (ja) 2013-10-09
NL1031538A1 (nl) 2006-10-10
MA29384B1 (fr) 2008-04-01
MX2007012419A (es) 2007-12-05
IL186085A0 (en) 2008-01-20
WO2006108599A3 (en) 2007-02-15
JP2008534024A (ja) 2008-08-28
EP1866412A2 (en) 2007-12-19
BRPI0608180A2 (pt) 2009-11-17
KR20080009072A (ko) 2008-01-24
GB2439673A (en) 2008-01-02
WO2006108599A2 (en) 2006-10-19
EA200701901A1 (ru) 2008-04-28
NL1033520A1 (nl) 2007-08-06
PE20061358A1 (es) 2007-01-13
CR9423A (es) 2007-12-17
AU2006233647A1 (en) 2006-10-19
TW200718781A (en) 2007-05-16
GB0719489D0 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
AR052741A1 (es) Acidos nucleicos de union a ghrelin
NZ593447A (en) Inhibition of hdac2 to promote memory
WO2007020457A3 (en) Labelled modified guanine- containing nucleosides and nucleotides comprising a fluorophore attached to the base through a linking group comprising a polyethylene glycol spacing group and methods for their use
ES2354696T8 (es) Planta que produce ácido hialurónico.
EA200900260A1 (ru) Гранулы и орально дезинтегрируемые таблетки, содержащие оксикодон
WO2007087310A3 (en) Nucleic acid analysis using sequence tokens
ITTO20030832A1 (it) Struttura di tubazione del carburante in veicolo di piccole dimensioni.
ITRM20040578A1 (it) Processo e impianto per il trattamento di pile esauste.
GT200600522A (es) Nueva asociación de un inhibidor de la corriente sinusal i, y de un inhibidor de la enzima de conversión y las composiciones farmacéuticas que la contienen
ITMI20030150A1 (it) Processo per preparare fluoroalogenoeteri.
ITMI20061987A1 (it) Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
TH74362A (th) วิธีการผลิตตัวเร่งปฏิกิริยาสำหรับใช้สังเคราะห์กรดเมธาคริลิก
ITTO20030598A1 (it) Chiave per dadi o bulloni antifurto.
ITVA20040015A1 (it) Inibitore di corrosione concentrato per miscele refrigeranti, metodo di produzione di miscele refrigeranti ed inibizione di miscele refrigeranti esaurite.
ITTO20020169U1 (it) Struttura migliorata di bullone anti-effrazione.
TH114021S (th) อ่างล้างหน้า
TH62532S (th) สาก
TH28394S1 (th) อิฐบล๊อก
ITRM20050005U1 (it) Tackle improver per incrementare la potenza del tackle del calciatore e per migliorarne la tecnica di esecuzione.
WO2006012365A3 (en) Protease inhibitor
TH29231S1 (th) อุปกรณ์ปลายทางสำหรับรับ-ส่งสัญญาณ
TH24652S1 (th) อิฐชนิดฉนวนกันความร้อน
ITMI20060136U1 (it) Collegamento ad innesto con un manicotto girevole ed un mandrino di ritenuta per l'alloggiamento di tubetti,barattoli o simili.
TH83811B (th) หน้าตัดโลหะ
TH78096S (th) อิฐบล็อก

Legal Events

Date Code Title Description
FA Abandonment or withdrawal